Maria JD - BioAffinity Technologies, President, Founder
| BIAF Stock | USD 1.24 0.03 2.36% |
Insider
Maria JD is President, Founder of bioAffinity Technologies,
| Age | 68 |
| Address | 22211 West Interstate 10, San Antonio, TX, United States, 78257 |
| Phone | 210 698 5334 |
| Web | https://www.bioaffinitytech.com |
BioAffinity Technologies, Management Efficiency
The company has return on total asset (ROA) of (0.6978) % which means that it has lost $0.6978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5152) %, meaning that it created substantial loss on money invested by shareholders. BioAffinity Technologies,'s management efficiency ratios could be used to measure how well BioAffinity Technologies, manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.39. The BioAffinity Technologies,'s current Return On Capital Employed is estimated to increase to -1.27. At this time, BioAffinity Technologies,'s Other Assets are most likely to decrease significantly in the upcoming years. The BioAffinity Technologies,'s current Fixed Asset Turnover is estimated to increase to 1.33, while Non Currrent Assets Other are projected to decrease to roughly 10 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| Simon Morriss | Genetic Technologies | 51 | |
| Bus FCI | Genetic Technologies | N/A | |
| Kelley Morgan | T2 Biosystms | 48 | |
| Brett Giffin | T2 Biosystms | 65 | |
| AGIA BCom | Genetic Technologies | N/A | |
| Annette Baumgartner | Psychemedics | N/A | |
| Sarah Ashby | Psychemedics | N/A | |
| Michael Esq | T2 Biosystms | 53 | |
| John CPA | T2 Biosystms | 66 | |
| Matthew Gage | Precipio | 57 | |
| Miri ChikoRadomski | Precipio | N/A | |
| Ahmed Sabet | Precipio | 38 | |
| Charles IV | Psychemedics | 58 | |
| Aparna MD | T2 Biosystms | 57 | |
| BBus CA | Intelligent Bio Solutions | 60 | |
| Werner Baumgartner | Psychemedics | N/A | |
| Alex Arzeno | Intelligent Bio Solutions | N/A | |
| Ayman MD | Precipio | 39 | |
| Carl BSc | Genetic Technologies | 69 | |
| Kevin Camilleri | Genetic Technologies | 47 | |
| Keith Meadors | Precipio | N/A | |
Management Performance
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 |
bioAffinity Technologies, Leadership Team
Elected by the shareholders, the BioAffinity Technologies,'s board of directors comprises two types of representatives: BioAffinity Technologies, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioAffinity. The board's role is to monitor BioAffinity Technologies,'s management team and ensure that shareholders' interests are well served. BioAffinity Technologies,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioAffinity Technologies,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Overton, Director Communications | ||
| Dallas Coleman, National Sales | ||
| William Bauta, Senior Therapeutics | ||
| Maria JD, President, Founder | ||
| Steven Girgenti, Founder Board | ||
| Xavier MS, VP Operations | ||
| Timothy JD, Secretary VP |
BioAffinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioAffinity Technologies, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (0.87) % | ||||
| Current Valuation | 20.76 M | ||||
| Shares Outstanding | 15.48 M | ||||
| Shares Owned By Insiders | 29.55 % | ||||
| Shares Owned By Institutions | 2.46 % | ||||
| Number Of Shares Shorted | 271.43 K | ||||
| Price To Book | 6.34 X |
Currently Active Assets on Macroaxis
When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.